TELUS International (Cda) experienced a significant drop in shares on Friday morning, following a downward revision of its parent company's outlook for the full year. The weak performance of its Telus International unit led to this unfavorable development. As of 9:35 a.m. ET, shares in Toronto were down nearly 29% at 13.76 Canadian dollars ($10.49), while the stock in New York … [Read more...] about TELUS International (Cda) Faces Steep Decline in Shares
AT&T Stock Plunges as J.P. Morgan Downgrades Rating
Shares of AT&T Inc. sank to a nine-month low on Friday after J.P. Morgan downgraded the telecommunications giant. The downgrade was a result of slowing growth drivers and uncertainty surrounding potential liabilities related to lead-sheathed cables. Analyst Downgrades Rating and Lowers Price Target Analyst Philip Cusick, who had previously given AT&T an overweight … [Read more...] about AT&T Stock Plunges as J.P. Morgan Downgrades Rating
The Business World’s Priorities in Cloud Spending
The dominance of artificial intelligence (AI) and machine learning (ML) in discussions surrounding technology may mislead some into thinking that these are the top priorities for executives when it comes to cloud spending. However, according to a survey conducted by Jefferies analyst Brent Thill, chief information officers (CIOs) from 40 U.S. companies have revealed a different … [Read more...] about The Business World’s Priorities in Cloud Spending
Consumers Adapt to Inflationary Pressures
Consumers are displaying a heightened sensitivity to inflationary pressures and are actively seeking ways to stretch their budgets, according to PepsiCo Inc. Chief Executive Ramon Laguarta. Laguarta revealed during the company's second-quarter earnings call that consumers are expanding their shopping horizons, exploring multiple stores in search of better deals. They are … [Read more...] about Consumers Adapt to Inflationary Pressures
Moleculin Biotech Announces Positive Results From Phase 1 Clinical Trial of Annamycin
Moleculin Biotech, a clinical stage pharmaceutical company, has reported encouraging data from a Phase 1 clinical trial of their drug, annamycin. The study revealed no evidence of cardiotoxicity in the subjects treated with the drug. As a result, Moleculin Biotech's shares soared by 17% to 72 cents. Despite experiencing a 33% decline in the stock value this year, this recent … [Read more...] about Moleculin Biotech Announces Positive Results From Phase 1 Clinical Trial of Annamycin